With the remarkable success of anti-PD-1 therapy limited to a fraction of patients, the field is actively working to identify and test new T cell targets to extend the benefits of immunotherapy to a larger group of cancer patients while reducing chances of immune related adverse events. This evidence concerns the gene PDCD1 and cancer.